Quantitative modelling predicts the impact of DNA methylation on RNA polymerase II traffic

Significance We introduce an interdisciplinary approach to understanding global modulation of gene expression in mammalian cells. Conventional transcription factors target a limited subset of genes, whereas global modulators bind the genome broadly. An example of the latter is MeCP2, which is mutated in neurological disorders. MeCP2 has millions of genomic binding sites, but its effects on gene expression are mostly small scale and incompletely understood at a mechanistic level. Using datasets from genetically modified human neurons, our mathematical approach rigorously distinguishes global effects from experimental noise. This allows us to integrate theory with experiments to discriminate competing mechanistic models. The results indicate that MeCP2 creates “roadblocks” in gene bodies that slow down elongating RNA polymerase II, leading to polymerase queueing. Patterns of gene expression are primarily determined by proteins that locally enhance or repress transcription. While many transcription factors target a restricted number of genes, others appear to modulate transcription levels globally. An example is MeCP2, an abundant methylated-DNA binding protein that is mutated in the neurological disorder Rett syndrome. Despite much research, the molecular mechanism by which MeCP2 regulates gene expression is not fully resolved. Here, we integrate quantitative, multidimensional experimental analysis and mathematical modeling to indicate that MeCP2 is a global transcriptional regulator whose binding to DNA creates “slow sites” in gene bodies. We hypothesize that waves of slowed-down RNA polymerase II formed behind these sites travel backward and indirectly affect initiation, reminiscent of defect-induced shockwaves in nonequilibrium physics transport models. This mechanism differs from conventional gene-regulation mechanisms, which often involve direct modulation of transcription initiation. Our findings point to a genome-wide function of DNA methylation that may account for the reversibility of Rett syndrome in mice. Moreover, our combined theoretical and experimental approach provides a general method for understanding how global gene-expression patterns are choreographed.

[1]  Leander M. Sinanan,et al.  Structural Basis of MeCP2 Distribution on Non-CpG Methylated and Hydroxymethylated DNA. , 2017, Journal of molecular biology.

[2]  A. Bird,et al.  MeCP2 recognizes cytosine methylated tri-nucleotide and di-nucleotide sequences to tune transcription in the mammalian brain , 2017, PLoS genetics.

[3]  C. Dean,et al.  Slow Chromatin Dynamics Allow Polycomb Target Genes to Filter Fluctuations in Transcription Factor Activity , 2017, Cell systems.

[4]  A. Bird,et al.  Structure of the MeCP2–TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders , 2017, Proceedings of the National Academy of Sciences.

[5]  I. Dodd,et al.  Directing traffic on DNA—How transcription factors relieve or induce transcriptional interference , 2017, Transcription.

[6]  Harrison W. Gabel,et al.  DNA methylation in the gene body influences MeCP2-mediated gene repression , 2016, Proceedings of the National Academy of Sciences.

[7]  A. Bird,et al.  Efficient and versatile CRISPR engineering of human neurons in culture to model neurological disorders , 2016, Wellcome open research.

[8]  Harrison W. Gabel,et al.  Disruption of DNA methylation-dependent long gene repression in Rett syndrome , 2015, Nature.

[9]  John T. Lis,et al.  Getting up to speed with transcription elongation by RNA polymerase II , 2015, Nature Reviews Molecular Cell Biology.

[10]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[11]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[12]  Howard Y. Chang,et al.  Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.

[13]  A. Bird,et al.  Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor , 2013, Nature Neuroscience.

[14]  S. Henikoff,et al.  Regulation of nucleosome dynamics by histone modifications , 2013, Nature Structural &Molecular Biology.

[15]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[16]  G. Hon,et al.  Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome , 2012, Cell.

[17]  Sündüz Keles,et al.  Normalization of ChIP-seq data with control , 2012, BMC Bioinformatics.

[18]  Tanja Waldmann,et al.  Rapid, complete and large‐scale generation of post‐mitotic neurons from the human LUHMES cell line , 2011, Journal of neurochemistry.

[19]  Felix Krueger,et al.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..

[20]  Feng Lin,et al.  A signal-noise model for significance analysis of ChIP-seq with negative control , 2010, Bioinform..

[21]  S. Peters,et al.  The MECP2 duplication syndrome , 2010, American journal of medical genetics. Part A.

[22]  Robert S. Illingworth,et al.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. , 2010, Molecular cell.

[23]  Julien F. Ollivier,et al.  Colored extrinsic fluctuations and stochastic gene expression , 2008, Molecular systems biology.

[24]  R. Ghosh,et al.  MeCP2-Chromatin Interactions Include the Formation of Chromatosome-like Structures and Are Altered in Mutations Causing Rett Syndrome* , 2007, Journal of Biological Chemistry.

[25]  R. A. Blythe,et al.  Nonequilibrium steady states of matrix-product form: a solver's guide , 2007, 0706.1678.

[26]  A. Bird,et al.  Reversal of Neurological Defects in a Mouse Model of Rett Syndrome , 2007, Science.

[27]  A. Harel-Bellan,et al.  The histone variant mH2A1.1 interferes with transcription by down-regulating PARP-1 enzymatic activity. , 2006, Genes & development.

[28]  A. Bird,et al.  DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. , 2005, Molecular cell.

[29]  M. Nakao,et al.  Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain , 2003, Journal of medical genetics.

[30]  A. Bird,et al.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome , 2001, Nature Genetics.

[31]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[32]  A. Bird,et al.  Identification and Characterization of a Family of Mammalian Methyl-CpG Binding Proteins , 1998, Molecular and Cellular Biology.

[33]  B. Derrida AN EXACTLY SOLUBLE NON-EQUILIBRIUM SYSTEM : THE ASYMMETRIC SIMPLE EXCLUSION PROCESS , 1998 .

[34]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[35]  A. Bird,et al.  MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin , 1997, Cell.

[36]  A. Bird,et al.  Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. , 1993, Nucleic acids research.

[37]  A. Bird,et al.  Purification, sequence, and cellular localization of a novel chromosomal protein that binds to Methylated DNA , 1992, Cell.